Pediatric intestinal failure associated liver disease (IFALD) is associated with a high morbidity and mortality. Studies have suggested that when intravenous (IV) soybean oil (SO) is replaced with fish oil (FO), direct hyperbilirubinemia is more likely to resolve. The necessary duration of FO has not been established. This study seeks to determine if 24 weeks of FO is an effective and safe therapy for IFALD.
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Introduction
Parenteral nutrition (PN) is a major contributing factor to the long-term survival of children with intestinal failure (IF) 1 . IF results in prolonged PN dependence secondary to intestinal malabsorption. With an incidence of 3-5 cases per 100,000 births, IF in children is commonly caused by shortened and/or dysfunctional bowel due to necrotizing enterocolitis and congenital gastrointestinal disorders such as gastroschisis, intestinal atresias and volvulus [1] [2] [3] [4] . For children with IF, PN serves as a bridge to bowel adaptation, a process by which the intestine recovers and improves its absorptive capacity. During this time, PN provides necessary fluids and micro-and macronutrients to prevent dehydration and promote growth and neurodevelopment.
The process of bowel adaptation can take weeks to years and can be complicated by intestinal failure associated liver disease (IFALD) which in turn is associated with a high morbidity and mortality 1, 3, [4] [5] [6] [7] . Pediatric IFALD is hallmarked by cholestasis exhibited biochemically by direct hyperbilirubinemia, elevated serum liver transaminases, and histological findings on liver biopsy including cholestasis, steatosis, lipidosis and eventually fibrosis and cirrhosis. As IFALD progresses, patients can develop end stage liver disease exhibited by ascites, coagulopathy, portal hypertension, and hepatic encephalopathy. While an isolated intestine or combined liver-intestine transplantation may be life-saving for children with IF, these may not be feasible options for some children because of their small size, co-morbidities, and lack of timely organ availability 8 . The wait-list mortality rate for children awaiting a combined liver-intestine transplantation has historically been much higher than those awaiting transplantation of other solid organs 8 . For those who receive a transplant, the five-year survival is 50-70% and can be complicated by graft rejection, infection, and malignancy 1, 8 .
The safest and most effective treatment for IFALD remains successful rehabilitation to full enteral nutrition. However, enteral autonomy in children with IF may take time, or may not be feasible at all due to a host of factors. Moreover, IFALD has been shown to develop as early as a few weeks to months after PN initiation, particularly in low birth weight infants 5, [9] [10] [11] .
Intravenous (IV) fatty acid emulsions are prescribed with PN to provide additional calories, prevent essential fatty acid deficiencies, promote growth and neurodevelopment, and The development of IFALD in children has been associated with the composition and dose of fatty acid emulsions [9] [10] [11] [12] [13] [14] [15] . Animal studies, case reports and cohort studies have provided encouraging evidence that when 1g/kg/d of exclusive FO is substituted for SO, biochemical IFALD is more likely to resolve [9] [10] [11] [12] [13] [16] [17] [18] [19] . However, the required duration of FO monotherapy is unknown because prior studies usually prescribe FO until PN discontinuation [9] [10] [11] . Despite these reports and increased experience with FO at several US centers, there remain significant barriers for administering FO to IF patients due to a much higher unit cost, lack of FDA approval, and uncertainty of long-term safety and efficacy.
From the available studies in the literature, biochemical reversal of IFALD with FO monotherapy has been shown to occur between 35 days and 24 weeks [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . We sought to determine whether a finite period of FO monotherapy followed by resumption of SO and and unforeseen adverse events, specifically effects on growth and neurodevelopment 9, 12, 20, 21 .
Methods

Patient Population
Ten interventional subjects were recruited from the University of California, Los Angeles 
Study Procedures and Methods
Once enrolled, each of the 10 interventional subjects received 0. The probabilities of experiencing cholestasis resolution across time were estimated using the Kaplan-Meier method. The Kaplan-Meier curves were compared between the groups using the log rank test.
Growth for FO subjects was assessed by Z-scores. All anthropometric measurements were corrected for prematurity if the subject was less than two years of age. Mean and standard deviations for weight, length and head circumference were obtained for the Center for Disease
Control and Prevention (CDC).
A p-value < 0.05 was considered statistically significant.
Results
Baseline characteristics between the FO and SO groups were similar (Table 1) . While not statistically significant, the FO group was older at the start and end of the study. The study population was premature with a median gestational age of 34 weeks in both groups. The primary gastrointestinal diagnoses for the two groups were similar. FO and SO's median number of gastrointestinal surgeries and mean small bowel length, if measured and recorded by the surgeon, were comparable. The majority of the subjects had surgical short bowel syndrome.
The median small bowel length (range) was 23 cm (0-51 cm) and 27 cm (0-55 cm) in the FO and SO group, respectively. As defined, IF was present in 80% of the FO group and 55% of the SO group.
PN at the beginning and end of the study was comparable between the two groups with respect to duration, total calories, glucose delivery rate, and amino acid dose (Table 2) .
However, at the start and end of the study, the mean intravenous fat dose (±SD) was less in the (Figure 1 ).
Primary Outcome
Median follow-up time for the primary endpoint for the time to resolution of cholestasis was 11.5 weeks (range 2.4 -18 weeks) and 24 weeks (range 5.4 -24 weeks) for the FO and SO group, respectively. 70% (7 subjects) of the FO group experienced resolution of cholestasis, while 5% (1 subject) of the SO group experienced resolution of cholestasis. The Kaplan-Meier method estimates (±SEM) that 75% (±16%) in the FO group will experience resolution of cholestasis by 17 weeks vs. 6% (±6%) in the SO group will experience resolution of cholestasis by 17 weeks (p < 0.0001) (Figure 2 ). After 11.5 weeks of FO monotherapy, 50% of subjects will biochemically reverse their IFALD. The hazard risk ratio for resolution of cholestasis was 21.5
(95% confidence interval (3.8, 404)) for the FO group while it was 0.05 (95% confidence interval (0.0002, 0.26)) for the SO group (p=0.0002).
Secondary and Tertiary Outcomes
There was no difference in death, transplant, percentage of patients on full enteral feeds, number of readmissions, number of inpatients days, and percentage of subjects with normalization of liver function tests (Table 3) . 20% of FO subjects expired, while 10% of SO subjects expired (two subjects vs. one subject). 10% of subjects in the FO and SO group received a transplant (one subject vs. two subjects). Both FO subjects who died were diagnosed with septic shock and medical care was withdrawn because continuation of care was considered futile. While one FO subject who died demonstrated hepatic deterioration, the other subject's cholestasis had resolved. The two deaths in the SO group were attributed to liver failure. 
Safety
Follow-up
Eight subjects including the one subject who received a transplant were alive at the end of FO intervention. When FO was discontinued, six of the eight subjects (75%) remained PN dependent and were transitioned to SO with a mean dose of 0.9 g/kg/d (range 0.6-1 g/kg/d). One subject was not available for long-term follow-up. Subjects were followed for a median 1.9 years (range one-two years). During follow-up, one subject remained free of cholestasis and In this study, the FO and SO group were at high risk for complications from IF based on their prematurity, low volumes of enteral nutrition, unfavorable gastrointestinal anatomy, and baseline serum direct bilirubin concentrations and liver function tests. Neonates born premature and with congenital or acquired gastrointestinal disorders are at high risk for IFALD because they are exposed to long PN courses due to intestinal dysfunction 3, 5, 6 . Predisposing factors for these populations include an immature biliary system, small for gestational age, necrotizing enterocolitis, abdominal surgeries, intestinal resections, and sepsis 3, 4, 22, 23 . All of these factors center around insufficient enteral intake. As gestational age decreases and baseline serum bilirubin concentrations increase, resolution of IFALD with FO appears to be less likely 11 .
Children with congenital gastrointestinal disorders are predisposed to develop IFALD 5, 14 .
As serum bilirubin concentrations climb, so does mortality 7, 11 . In comparison to babies who are not jaundiced, mortality in neonates with congenital gastrointestinal disorders with a conjugated 11 bilirubin > 2 mg/d increases from 2 to 17% 7 . In fact, 38% of patients with a conjugated bilirubin ≥ 10 mg/dL will die or require a transplant referral 7 . Premature neonates and those with ultrashort gut, intestinal discontinuity, without distal ileum and/or an ileocecal valve, and repeated episodes of sepsis are at highest risk 1, 6, 5, 23 .
PN-specific contributors to IFALD include PN duration and an excess, deficiency, or imbalance in PN macro-or micronutrients 5, 24 . In this study, glucose delivery rate and amino acid dose were comparable, and baseline median PN duration was 137 and 72 days in the FO and SO group, respectively. Reflecting changes in medical practice, the FO group was receiving less SO (g/kg/d) at baseline than historical controls [14] [15] . After FO termination, subjects were prescribed PN with a low dose of SO (mean 0.9 g/kg/d goal with a median time of 9-12 weeks 9,10 . In addition to gestational age and severity of IFALD, co-morbidities, enteral nutrition at baseline, the intestine's ability to adapt, and number of septic episodes and abdominal surgeries during treatment may serve as predictors of FO nonresponders and slow responders 11, 27 .
A major confounding factor of all FO studies, including our study, has been the dose of the lipid product [9] [10] [11] [12] [13] [14] Randomized controlled trials have demonstrated that emulsions composed of various types of oils can prevent and reverse IFALD [28] [29] [30] [31] [32] [33] [34] . SMOF® (Fresenius Kabi, Bad Homberg, Germany), an emulsion comprised of some FO and SO, along with medium chain triglycerides in the form 13 coconut oil and monounsaturated fatty acids in the form of olive oil has been associated with improved liver function and can be dosed ≥ 1 g/kg/d [28] [29] [30] [31] [32] . A mixed emulsion may be more physiological, better satisfy fatty acid requirements, and preserve or improve growth and neurodevelopment in a nutritionally vulnerable population.
FO's mechanism is likely multifactorial. While SO is made up of the essential polyunsaturated fatty acids, linoleic and ∝-linolenic acid, it predominantly contains omega-6 fatty acids. FO, on the other hand, is mainly comprised of the omega-3 fatty acids, eicosapentaenoic and docosahexaenoic acid, which are absent in SO, but can be synthesized from ∝-linolenic acid. Linoleic acid is converted to arachidonic acid, which generates inflammatory prostaglandins, leukotrienes, and thromboxanes. ∝-linolenic acid is metabolized to eicosapentaenoic and docosahexaenoic acid, which are known for their anti-inflammatory properties and role in visual and cognitive development. By the "traditional" definition, essential fatty acids must be consumed in the diet and cannot be synthesized de novo. However, in the premature and SBS population, specifically those with cholestasis, provision and absorption of endogenous fatty acids may be limited 35, 36, 37 . At the same time, production of downstream products may be insufficient because of an increased demand or deficiencies of desaturase enzymes. Placental transfer of polyunsaturated fatty acids mainly occurs in the third trimester, thereby increasing the risk for deficiencies in preterm babies 37 . As a result, PN dependent neonates whose lipid source is SO have increased omega-6:omega-3 fatty acid ratios, thereby promoting inflammation and hepatic injury 38 .
Polyunsaturated fatty acids promote lipid peroxidation. In order to minimize oxidative stress, PN is protected from light and vitamin E is added. The amount of vitamin E in SO may be inadequate and is in the form, ϒ-tocopherol, which is not as effective in preventing free radical generation when compared to α-tocopherol, which FO contains and is provided in a much larger concentration. Moreover, preterm and SBS children are deficient in vitamin E because they lack exogenous sources and have decreased adiposity 39 .
While SO contains a high amount of phytosterols, FO lacks phytosterols. Phytosterols reduce biliary flow by antagonizing the farnesoid X receptor, a bile acid nuclear receptor that regulates the multi-drug resistant genes 1 and 2 (mdr 1 and 2). These genes encode Pglycoproteins that are responsible for promoting bile acid secretion [40] [41] [42] [43] . Animal studies have demonstrated that FO increases biliary flow, while SO impairs flow 44 . As a result, it is not surprising that bilirubin profiles improve prior to other hepatocellular indices as described in this study and other studies [9] [10] [11] [12] .
There are concerns that FO may cause an essential fatty acid deficiency. This study supports previous findings, which suggests that FO contains sufficient omega-6 fatty acids to prevent the development of an essential fatty acid deficiency as measured by a triene-tetraene ratio. While we used a liberal cut-off, a triene:tetraene ratio ≥ 0.5, the mean triene:tetraene ratio was between 0.01-0.02 9 . Triene:tetraene ratios, however, should be used with caution for detecting omega-6 and -3 fatty acid deficiencies. When absolute concentrations of specific polyunsaturated fatty acids are measured, there could be fatty acid deficiencies and toxicities with FO and SO. In order to develop an essential fatty acid by means of a triene:tetraene ratio, there must be an increase in mead acid, and decrease in arachidonic acid. Because desaturase enzymes have a higher affinity for omega-3 fatty acids, mead acid production many not increase with FO, which has adequate provisions of ∝-linolenic acid and high concentrations of eicosapentaenoic and docosahexaenoic acid.
One concern with lipid minimization is the decreased caloric intake from fat and possible adverse effects on growth and neurodevelopment. Premature and SBS children have high rates of growth failure and developmental delays 3, [45] [46] [47] [48] . This study, along with other SO lipid minimization and FO studies, have not reported a change in short-term growth 9, 15 . While there was improvement in the Z-score for length, overall growth in our study population was suboptimal. Long-term studies are lacking and needed. In order to make-up for decreased fat calories, clinicians may increase glucose delivery rates, which may promote lipid deposition in the liver and peripheral tissues, IFALD, hyperinsulinemia, and carbon dioxide retention 24 .
Lastly, because FO is antithrombotic, there is a theoretical concern that FO can increase the risk of bleeding in a population whose baseline risk is already increased. Similar to previous studies, there was no increase in bleeding, and INR and platelet counts remained unchanged or improved [9] [10] [11] .
While FO appears to be associated with a biochemical reversal of IFALD, it is unclear if transplant-free survival is altered. Liver and intestine transplants are life-saving and mortality rates continue to improve with modern medicine and surgery. In our study, transplant represented an important modality for two subjects to achieve a PN-free state without cholestasis. One subject achieved this goal during FO intervention, and the other subject later satisfied this goal during follow-up.
Data on FO's effect on liver histology is lacking, and while cholestasis may reverse, it is unclear if portal hypertension or fibrosis can be reversed 49 . In the setting of IFALD, animal and human studies have demonstrated that biochemical parameters may be imprecise [49] [50] . Moreover, while some studies have associated parenteral omega-3 fatty acids with hepatic collagen deposition, others have demonstrated improved histology on liver biopsy [51] [52] . Despite 24 weeks of FO and biochemical IFALD resolution, one of our subjects continued to demonstrate advanced fibrosis on liver biopsy requiring a transplant. Some patients regardless of a positive FO response may ultimately require an intestinal transplant with or without a liver because of prolonged IF, repeated episodes of sepsis and catheter replacements, severe malnutrition, or unchanged or progressive liver fibrosis. Others may opt for a transplant for quality of life issues and the desire to be PN-free.
Limitations of this analysis include the use of historical controls, missing data in the historical cohort, interpolation for laboratory data. In attempt to overcome problems associated with historical controls, the sample size for the control cohort was doubled. While subjects were not matched on specific confounding variables, they were relatively similar with regards to most baseline characteristics except for enteral nutrition, entry SO dose, lipid dose at the end of the study, and gastrointestinal surgeries. These factors, except for gastrointestinal surgeries, would positively favor the primary outcome, and cannot be ignored. Moreover, in the past 10 years, a multi-disciplinary approach to IF has been utilized at our institution, which has been associated with an improved prognosis for IF patients 54, 55 .
In addition, considering the number of comparisons made between the two cohorts, there is an increased risk of a type I error. A priori, we opted not to adjust for multiple comparisons.
Our goal was to clearly define the cohorts' risk factors for IFALD and associated complications.
While the study remains open and data continues to be collected, follow-up post-24
weeks of FO will be essential to determine if patients who continue on PN and restart SO remain free of cholestasis and if transplant-free survival is decreased.
Conclusion
17
The goal for IF patients is to safely bridge them to enteral autonomy or transplant if needed. A contemporary, multi-disciplinary approach to IFALD, with attention to nutrition, infection control, gastrointestinal surgeries, and the psychosocial dynamics of the family unit, cannot be underestimated. While FO monotherapy may play an important role in the treatment of this disease, attention must still be given to IFALD prevention and other factors that drive the development and progression of this disease. Long-term follow-up on growth and neurodevelopment are lacking. This report provides support for the safety and efficacy of FO for a finite period in the pediatric IFALD population. Table 3 . Secondary and tertiary outcomes for the fish oil (FO) and soybean oil (SO) group.
Results are either as medians with the corresponding range, or a percentage (n).
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22 To date, there has yet to be a masked randomized controlled trial comparing FO to SO in children with advanced IFALD. Considering this report, along with previously published data, such a trial would most likely be considered unethical and not feasible due to the demand for FO and high mortality associated with advanced IFALD [9] [10] [11] [12] . At time this study was designed, there was a lack of equipoise and unwillingness among investigators, clinicians, and parents/legal guardians to randomize a potentially eligible subject with advanced IFALD to either FO or SO even with a cross-over design. As a result, it was decided, a priori, to use historical controls as a comparison group. In order to overcome some of the limitations associated with historical controls, the control sample size was doubled and controls satisfied applicable inclusion and exclusion criteria. Matching, based off of gender, gestational age, and/or primary gastrointestinal diagnosis, was attempted but not possible due to the limited number of historical controls.
The historical controls were similar to controls except for two variables: lipid dose and enteral feeds. At the time of enrollment, the FO group was receiving less SO and more enteral feeds when compared to SO-two factors that would positively favor the primary outcome.
Another pitfall associated with historical controls is that prevention strategies and treatments for IF and IFALD have drastically changed since the initiation of this study, all of which are associated with improved outcomes 54 .
All laboratories performed to assess the efficacy and safety of FO were performed as part of standard of care. It would not have been feasible to mandate laboratory visits for solely for research purposes at specific time intervals (ie exactly at week 4, 8, etc) for a variety of reasons.
In general, children with IFALD undergo laboratory assessment for the progression or regression of IFALD on a bi-weekly to monthly basis depending on illness severity. Moreover, this population is at high risk for contamination of their central venous catheters and anemia.
Accessing a subject's catheter for research purposes would increase infection risk. In addition, additional blood draws outside of standard, routine medical care, would potentially worsen a subject's anemia, putting him/her at risk for needing a red blood cell transfusion or iron infusion.
Transfusion exposure is generally limited in this population because of the possible need for a multi-visceral transplant. Moreover, when red blood cells lyse, direct bilirubin is released, worsening a subject's cholestasis. As a result, labs evaluating efficacy and safety were limited to routine, standard care, which was dictated by the medical team. Moreover, routine laboratory assessment included all of the necessary assessments for this study.
Laboratory values were collected at baseline and then by weekly intervals for 24 weeks for each subject. If a subject had multiple values available for a specific time interval, the first value was taken. An alternative method would be to calculate the average if multiple value were available for a specific time interval. For the analysis, for reasons of simplicity and clinical interpretation, baseline and study weeks 4, 8, 12, 16, 20 and 24 were analyzed. As a result, there was a risk for missing data at specific time points. For example, a subject may have had a laboratory assessment for a specific biomarker at baseline and weeks 3, 5, 7, 10, 12, 16, 18, and 24. Data would then be missing at study weeks 4, 8, and 20. In order to account for this data, interpolation was used. The slope was calculated for the biomarker between two time points (ie study weeks 3 and 5), and this value was added to study week 3 in order to interpolate for week 4. In general, serum direct bilirubin and liver function tests follow an upward or downward trend and do not change drastically from one day to the next in the absence of culture proven sepsis. Other options to account for missing data would include: last observation carried forward, taking the mean of a specific time interval and using this mean for the missing time interval (ie study weeks 1, 2, and 3 for study week 4), or bootstrapping. Overall, the method used to account for missing data, appears to be the most biologically plausible and appropriate for this study. In order to determine if this method was accurate, the analysis for serum direct bilirubin was performed without interpolation. In general, when these results are compared to the results with interpolation ( Figure 1A ), they appear similar (Appendix, Figure 1 ). As anticipated, there were less data points available for analysis without interpolation (Appendix, Table 1 ).
Another reason for missing data is death or enteral autonomy (discontinuation of PN).
Approximately 10-20% of the population expired during the study. In cases of enteral autonomy, laboratory assessments may not be performed as frequently while receiving PN because direct hyperbilirubinemia would be anticipated to resolve over time. Ten to 15% of the study population achieved enteral autonomy. In both these situations when laboratory values
were not available beyond a certain time point, extrapolation was not used.
In conclusion, this report provides support that FO biochemically reverses IFALD. In order to determine if long-term transplant-free survival, long-term follow-up (4.5 years postintervention) for this cohort is in progress. Moreover, there is a need to determine the cost-effectiveness of FO considering the cost of FO and transplant. FO can cost approximately 50 to several hundred US dollars per day, while SO costs only a couple of dollars 56 . A transplant costs approximately 1.5-1.9 million dollars in the first year. Lastly, there is a paucity of human data attempting to understand how FO biochemically reverses IFALD. In order to better understand FO's mechanism, a biorepository of human blood samples has been established to investigate the link between phytosterols, erythrocyte polyunsaturated fatty acids, inflammation, and bile acid transport.
